Combining forces to hit cancer stem cells: TRAIL-lymphocytes and EpCAMxCD3 bispecific antibody show efficacy against pancreatic cancer

TRAIL selectively kills cancer cells while bispecific antibody EpCAMxCD3 guides effector lymphocytes to cancer cells. Arming of ex vivo constructed TRAIL-lymphocytes with EpCAMxCD3 enhances contact time and affinity between lymphocytes and tumor cells and enforces tumor elimination. This boosts endo...

Descripción completa

Detalles Bibliográficos
Autores principales: Herr, Ingrid, Groth, Ariane, Salnikov, Alexei V., Büchler, Markus W., Moldenhauer, Gerhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2012
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3429579/
https://www.ncbi.nlm.nih.gov/pubmed/22934267
http://dx.doi.org/10.4161/onci.19532
_version_ 1782241821613621248
author Herr, Ingrid
Groth, Ariane
Salnikov, Alexei V.
Büchler, Markus W.
Moldenhauer, Gerhard
author_facet Herr, Ingrid
Groth, Ariane
Salnikov, Alexei V.
Büchler, Markus W.
Moldenhauer, Gerhard
author_sort Herr, Ingrid
collection PubMed
description TRAIL selectively kills cancer cells while bispecific antibody EpCAMxCD3 guides effector lymphocytes to cancer cells. Arming of ex vivo constructed TRAIL-lymphocytes with EpCAMxCD3 enhances contact time and affinity between lymphocytes and tumor cells and enforces tumor elimination. This boosts endogenous immune responses and augments the effect of cytotoxic tumor therapy.
format Online
Article
Text
id pubmed-3429579
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-34295792012-08-29 Combining forces to hit cancer stem cells: TRAIL-lymphocytes and EpCAMxCD3 bispecific antibody show efficacy against pancreatic cancer Herr, Ingrid Groth, Ariane Salnikov, Alexei V. Büchler, Markus W. Moldenhauer, Gerhard Oncoimmunology Author's View TRAIL selectively kills cancer cells while bispecific antibody EpCAMxCD3 guides effector lymphocytes to cancer cells. Arming of ex vivo constructed TRAIL-lymphocytes with EpCAMxCD3 enhances contact time and affinity between lymphocytes and tumor cells and enforces tumor elimination. This boosts endogenous immune responses and augments the effect of cytotoxic tumor therapy. Landes Bioscience 2012-08-01 /pmc/articles/PMC3429579/ /pubmed/22934267 http://dx.doi.org/10.4161/onci.19532 Text en Copyright © 2012 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Herr, Ingrid
Groth, Ariane
Salnikov, Alexei V.
Büchler, Markus W.
Moldenhauer, Gerhard
Combining forces to hit cancer stem cells: TRAIL-lymphocytes and EpCAMxCD3 bispecific antibody show efficacy against pancreatic cancer
title Combining forces to hit cancer stem cells: TRAIL-lymphocytes and EpCAMxCD3 bispecific antibody show efficacy against pancreatic cancer
title_full Combining forces to hit cancer stem cells: TRAIL-lymphocytes and EpCAMxCD3 bispecific antibody show efficacy against pancreatic cancer
title_fullStr Combining forces to hit cancer stem cells: TRAIL-lymphocytes and EpCAMxCD3 bispecific antibody show efficacy against pancreatic cancer
title_full_unstemmed Combining forces to hit cancer stem cells: TRAIL-lymphocytes and EpCAMxCD3 bispecific antibody show efficacy against pancreatic cancer
title_short Combining forces to hit cancer stem cells: TRAIL-lymphocytes and EpCAMxCD3 bispecific antibody show efficacy against pancreatic cancer
title_sort combining forces to hit cancer stem cells: trail-lymphocytes and epcamxcd3 bispecific antibody show efficacy against pancreatic cancer
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3429579/
https://www.ncbi.nlm.nih.gov/pubmed/22934267
http://dx.doi.org/10.4161/onci.19532
work_keys_str_mv AT herringrid combiningforcestohitcancerstemcellstraillymphocytesandepcamxcd3bispecificantibodyshowefficacyagainstpancreaticcancer
AT grothariane combiningforcestohitcancerstemcellstraillymphocytesandepcamxcd3bispecificantibodyshowefficacyagainstpancreaticcancer
AT salnikovalexeiv combiningforcestohitcancerstemcellstraillymphocytesandepcamxcd3bispecificantibodyshowefficacyagainstpancreaticcancer
AT buchlermarkusw combiningforcestohitcancerstemcellstraillymphocytesandepcamxcd3bispecificantibodyshowefficacyagainstpancreaticcancer
AT moldenhauergerhard combiningforcestohitcancerstemcellstraillymphocytesandepcamxcd3bispecificantibodyshowefficacyagainstpancreaticcancer

Ejemplares similares